Rare Daily Staff
Indian and Irish startup CyGenica said it has raised $1.4 million in a seed fund investment round to accelerate validation of its proprietary technology that enables safe, targeted, and affordable intercellular drug delivery by addressing the problem of delivering large-molecule therapeutics into living cells without damaging them or triggering an adverse immune response.
SOSV led the seed financing with participation by the VOYAGER Health-Tech fund, David Rowan, founder of Voyagers.io and angel investors Sharaf Yamani and Sami Mikati.
CyGenica intends to utilize the investment to accelerate the development of its disruptive drug delivery technology for genome editing, seeking to be a key partner of biopharmaceutical companies in the advancement of cutting-edge therapeutics for cancer and rare diseases to improve patients’ health and quality of life.
“The challenge of delivering drugs for cancer and genetic therapies, be it genes/RNAs/CRISPRs across cell membranes without damaging the cells and triggering an adverse immune response remains a complex hurdle in the pharmaceutical industry,” said Nusrat Sanghamitra, co-founder and CEO of CyGenica. “Our technology functions like a universal USB drive. It acts as a nanomachine that can deliver multitudes of cargoes carrying molecular information such as drugs and genetic therapeutics in an efficient, targeted manner without any toxicity and minimum immunogenicity. This will revolutionize drug delivery and lead to better patient outcomes.”
Nusrat said the funding will help de-risk CyGenica’s technology, expand its leadership team, and take the company significantly closer to its goal of enabling safe and targeted intracellular delivery of genetic therapies for cancer and rare diseases.
Photo: Nusrat Sanghamitra, co-founder and CEO of CyGenica